AUSTRALIA NEWS: Australia completes Covid-19 vaccine trial due to HIV antibody symptoms

After consultation with the Australian Government, UQ and CSL have decided not to develop a vaccine candidate who has placed phase 2 and 3 clinical trials.

Australia on Friday halted the ongoing development of a Covid-19 vaccine holder as several participants in a preliminary trial produced HIV antibodies after receiving potential treatment.

No serious incidents or safety concerns were reported to 216 participants in the first phase of the v451 Covid-19 vaccine trial developed by the University of Queensland (UQ) in partnership with biotech company CSL, according to the statement.

However, data has shown that some patients have made the immune system resistant to fragments of the HIV protein (gp41), which was used to stabilize the vaccine, it said.

After consultation with the Australian Government, UQ and CSL have decided not to develop a vaccine candidate who has placed phase 2 and 3 clinical trials.

The vaccine was one of 4 Australian pledges to purchase and contracts were awarded for 51 million doses of the experimental drug.

UQ said that trial participants were fully informed of the potential for partial immune response to this protein component, however, it was not expected that the recommended antibody levels would interfere with specific HIV tests.

The university has said it is unlikely that the vaccine will cause infection, and routine follow-up tests have confirmed that no HIV virus is present.

The decision was made after institutional consultants consulted with experts working on the implications that the problem showed the vaccine was spreading to more people, it said.

Responding to the announcement, Australian Prime Minister Scott Morrison said dropping the case should show Australians that the Government and investigators were moving forward.

We are moving very fast but not at the wrong speed, ”he said, adding that the system was working properly and that Australians were safe, as usual.

The University of Queensland began the launch of phase 1 of v451 in July 2020, testing its safety and physical prowess in healthy volunteers.

It said the person registered for the vaccine had shown that it provided a strong response to the novel coronavirus and had a strong security profile.

However, significant changes will need to be made to well-tested HIV practices in the health care environment to address the release of this vaccine, according to the statement.

Although its makers have omitted other tests, the university said the phase 1 trial will continue to test how long HIV antibodies have been, adding that so far studies show that levels are already declining.

The University of Queensland also plans to submit full details of peer-to-peer publications.

The co-leader of the UQ vaccine, Professor Paul Young, said that although the vaccine could be revived, the team did not have enough time.

“Doing so will slow down progress for another 12 months or so, and while this is a difficult decision to make, the urgent need for a vaccine should be a priority for everyone,” Young said.

“I said at the beginning of the development of the drug that there are no guarantees, but it is very encouraging that the main technology method we have used has passed a major clinical trial. It is a safe and well-tolerated vaccine, producing a powerful effect to eradicate the virus we had hoped to see, ”he said.

Andrew Nash, Chief Scientific Officer of CSL noted that this result highlights the risk of failure associated with early drug development, as well as the complex testing involved in making decisions about what to detect in advance.

Responding to the announcement, Sanjaya Senanayake, an infectious disease specialist and Professor of Medicine at The Australian National University, said that while it was disappointing that the Australian immunization person had been removed from the table, it was not surprising that one of the many COVID-19 drugs failed.

As a global community, we are marred by unprecedented speed and success in developing the COVID-19 vaccine, ”said Senannayake.

Diego Silva from Sydney Health Ethics at the University of Sydney School of Public Health noted that although progress may seem inconsistent, from a research point of view, this is a breakthrough.

Negative results are just as important as scientific achievements, because they, in turn, are part of the evidence for future research, ”said Silva.

Recent Articles

Related Stories

Leave A Reply

Please enter your comment!
Please enter your name here

Subscribe Us Get the daily news in your inbox